India’s rail tech sector is on track for a historic transformation — from signaling to safety systems. Discover 5 companies ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

A legal challenge in Britain to try to ban sales of parts for Lockheed Martin F-35 jets that may end up in Israeli fighters ...

India's real estate revival has gained momentum, with large developers experiencing strong pre-sales, rising cash flows, and ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

The team at Surbana Jurong expects Singapore's private sector developers to adopt a more cautious approach, particularly if ...

Harvest Technology Group is one year ahead of its plan to reach profit as it focuses on achieving a positive EBITDA before ...

Sony's latest earnings figures show that the PlayStation 5 generation has made over $136 billion in sales revenue, but only has a 9.5% profit margin.

Five Below Inc (FIVE) reports a robust 19.5% sales increase and strategic store expansions, despite facing tariff challenges and leadership transitions.

Same-store sales are anticipated to increase 7% to 9%, the company said, ahead of the 5.4% growth Wall Street is expecting. Same-store sales increased 7.1%, beating the 6.7% forecast.